Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Webcast: Navigating new frontiers: Ways to find space in the future RA market

April 9, 2019 | Pharma, Webcast, healthcare, rheumatoid arthritis 

In partnership with pharmaphorum

View the webcast »

The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors, are shaking up a once-stable market.

Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case for much longer, as several other candidates reach late-stage development.

Analysis of Therapy Watch data, a real-time syndicated market tracking tool and Living Withdata, our syndicated patient report series shows that JAK inhibitors have already made a strong impression in the European RA market, where their convenient oral administration advantage may override cost considerations that would otherwise favour biosimilar uptake.

This webcast, held in partnership with pharmaphorum uses the latest intelligence from both physicians and patients to look at emerging trends in the RA market, how these will shape the RA market of tomorrow and how companies can best position themselves for future success.

Topics covered in the webcast include:

  • The European RA market
  • Current status and market situation of JAK inhibitors (key EU5 countries)
  • Uptake curve of JAKS compared to other new entrants and biosimilars
  • The patient profile and unmet needs in RA
  • Profile of physicians prescribing JAKS
  • Country differences
  • The future of new classes of JAK inhibitors

View the webcast »

This content was provided by Inizio

Company Details

- PMLiVE

Inizio

Email
Website

 Latest Content from  Inizio 

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist

Hiding between the lines of any company’s ledgers is an intangible asset, invisible to most auditors, but with the potential to have a very real impact on bottom line. Pharma...

Webcast: Rich in potential – Exploring the opportunity for nutritionals in emerging markets

Watch the webcast: http://bit.ly/2oTpzFjA shift to preventative health has seen nutritionals emerge as a rapidly developing area in recent years. But while growth begins to level off in more established territories,...

A researcher’s guide to Key Driver Analysis

Research Manager Kayleigh Simpson explores how Key Driver Analysis can be used to answer key business

Research Partnership sends a cheque for $10,000 to Forever Angels

Helping them in their mission of caring for and improving the lives of orphans and abandoned infants in Tanzania

Pharma Market Research Conference, 2018

We are delighted to be presenting and exhibiting at PMRC, 14-15 February in Newark, NJ.

Out of the shadows: Mental health in the Asia Pacific region

In the first of a series of articles exploring mental health in emerging markets we take an in-depth look at the situation in Asia

Research Partnership has published a new patient Living with Atopic Dermatitis (US) report

Living with Atopic Dermatitis (AD) is a report based on a new study conducted amongst adult sufferers and parents of child sufferers. The report consists of 45-minute quantitative and 30-minute qualitative...

Research Partnership has published a new patient Living with Psoriasis (EU) report

Living with Psoriasis is a report based on a new study conducted in the main 5EU markets and Belgium and the Netherlands (reports can be purchased for either 5EU or 7EU)....

New opportunities in emerging markets

Published in Pharma Exec January 2018 by Rachel Howard

Webinar: Portfolio tracking for success

Thursday 18th January 2018 11:00 EST / 16:00 GMT / 17:00 CEST